Dr Andrew Sutherland

Research Unit



Senior Research Officer

Professional Experience

2018 – present Honorary Fellow, University of Melbourne
2013 – present Senior Research Officer, St Vincent’s Institute of Medical Research
2009 – 2012    Research Fellow, Harvard Medical School/Brigham and Women’s                             Hospital
2006 – 2009    Research Fellow, Harvard School of Public Health
2002 – 2005    PhD Immunology, Garvan Institute of Medical Research/University                           of New South Wales
2000 – 2001    Research Assistant, Garvan Institute of Medical Research
1996 – 1999     BSc (Hons I) Biochemistry and Molecular Genetics, University of                               New South Wales


2017 – 2021    Juvenile Diabetes Research Foundation International Career                                    Development Award
2016 – 2017    Diabetes Australia Millennium Award Type 1 Diabetes
2010 – 2012    Juvenile Diabetes Research Foundation International postdoctoral                           fellowship
2007 – 2009    CJ Martin postdoctoral fellowship, NHMRC Australia
2002 – 2005    Australian Postgraduate Award postgraduate scholarship
                         University of New South Wales, Faculty of Medicine postgraduate                             scholarship
                         Cooperative Research Council for Asthma postgraduate                                           scholarship
                         Garvan Institute of Medical Research postgraduate                                                    scholarship

Research Interests

Immune tolerance
Type 1 diabetes and autoimmune diseases
Immune therapies

Selected Publications

  1. Elso CM, Scott NA, Mariana L, Masterman EI, Sutherland AP, Thomas HE and Mannering SI. Replacing murine insulin 1 with human insulin protects NOD mice from diabetes. PLoS ONE, 2019, 14(12): e0225021
  2. Sutherland AP*, Graham KL*, Papadimitriou M, Gaurang J, Trivedi PM, Catterall T, Fynch S, Kay TWH and Thomas HE. IL-21 regulates SOCS1 expression in autoreactive CD8+ T cells but is not required for acquisition of CTL activity in the islets of non-obese diabetic mice. Scientific Reports, 2019, 9: 15302
  3. Stanley WJ, Trivedi PM, Sutherland AP, Thomas HE and Gurzov EN. Differential regulation of pro-inflammatory cytokine signaling by protein tyrosine phosphatases in pancreatic b-cells. Journal of Molecular Endocrinology, 2017, 59 (4): 325-37.
  4. Wali JA, Thomas HE and Sutherland AP. Linking obesity with type 2 diabetes: the role of T-bet. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2014, 2014(7): 331-340
  5. Sutherland AP, Joller N, Michaud M, Liu SM, Kuchroo VK and Grusby MJ. IL-21 promotes CD8+ CTL activity via the transcription factor T-bet. Journal of Immunology, 2013, 190(8): 3977-84
  6. Liu SM, Sutherland AP, Zhang Z, Rainbow DB, Quintana FJ, Paterson AM, Sharpe AH, Oukka M, Wicker LS, Kuchroo VK. Overexpression of the CTLA-4 isoform lacking exons 2 and 3 causes autoimmunity. Journal of Immunology, 2012, 188: 155-162
  7. Weisel M, Crouse J, Bedenikovic G, Sutherland AP, Joller N, Oxenius A. Type-I IFN drives the differentiation of short-lived effector CD8+ T cells in vivo. European Journal of Immunology, 2011, 42(2): 320-329
  8. Sutherland AP*, Zhang H*, Zullo AJ, Zhang Y, Michaud M, Xie Z, Patti M-E, Zhang J, Grusby MJ, Zhang WJ.  Zinc finger protein Zbtb20 is essential for postnatal survival and glucose homeostasis. Molecular and Cellular Biology, 2009, 29(10): 2804-2815
  9. Sutherland AP*, Van Belle T*, Wurster AL, Suto A, Michaud M, Zhang D, Grusby MJ, von Herrath M.  IL-21 is required for the development of type 1 diabetes in NOD mice. Diabetes, 2009, 58(5): 1144-1155
  10. Walters S, Webster KE, Sutherland AP, Gardam S, Groom J, Liuwantara D, Marino E, Thaxton J, Weinberg A, Mackay F, Brink R, Sprent J, Grey ST. Increase CD4+ FoxP3+ T cells in BAFF-transgenic mice suppresses T cell effector responses.  Journal of Immunology, 2009, 182: 793-801
  11. Sutherland AP, Mackay F, Mackay CR. BAFF as a therapeutic target: a novel approach to immunomodulation in autoimmunity and cancer.  Pharmacology and Therapeutics, 2006, 112(3): 774-86
  12. Fletcher CA, Sutherland AP, Groom JR, Batten ML, Ng LG, Gommerman J, Mackay F.  Development of nephritis but not sialadenitis in autoimmune-prone BAFF transgenic mice lacking marginal zone B cells.  European Journal of Immunology, 2006, 36(9): 2504-14
  13. Ng LG, Ng CH, Woehl B, Sutherland AP, Huo J, Xu S, Mackay F, Lam KP.  BAFF co-stimulation of Toll-like receptor activated B-1cells.  European Journal of Immunology, 2006, 36(7): 1837-46
  14. Di Guisto DA, Sutherland AP, Jankova L, Harrop SJ, Curmi PM, King GC. Plasminogen Activator Inhibitor-2 is highly tolernant to P8 resiue substitution – implications for serpin mechanistic model and prediction of nsSNP activities. The Journal of Molecular Biology, 2005, 353(5): 1069-80
  15. Sutherland AP*, Ng LG*, Fletcher CA, Shum B, Newton R, Grey ST, Rolph MS, Mackay F and Mackay CR. BAFF augments certain Th1-associated inflammatory responses. The Journal of Immunology, 2004, 174: 5537-44
  16. Ng LG*, Sutherland AP*, Newton R, Qian F, Cachero TG, Scott ML, Thompson JS, Wheway J, Chtanova T, Groom J, Sutton IJ, Xin C, Tangye SG, Kalled SL, Mackay F, Mackay CR. B cell-activating factor belonging to the TNF family (BAFF)-R is the principal BAFF receptor facilitating BAFF costimulation of circulating T and B cells. The Journal of Immunology, 2004, 173: 807-17
  17. Chtanova T, Kemp RA, Sutherland AP, Ronchese F, Mackay CR. Gene microarrays reveal extensive differential gene expression in both CD4+ and CD8+ type 1 and type 2 T cells. The Journal of Immunology, 2001, 167: 3057-3063

*These authors contributed equally to the work